1. Bai Y, Mi W, Meng X, Dong B, Jiang Y, Lu Y, Yu Y. Hydrogen alleviated cognitive impairment and blood-brain barrier damage in sepsis-associated encephalopathy by regulating ABC efflux transporters in a PPARalpha-dependent manner. BMC Neurosci 2023; 24: 37.
2.
Catarina AV, Branchini G, Bettoni L, De Oliveira JR, Nunes FB. Sepsis-associated encephalopathy: from pathophysiology to progress in experimental studies. Mol Neurobiol 2021; 58: 2770-2779.
3.
Chaudhry N, Duggal AK. Sepsis associated encephalopathy. Adv Med 2014; 2014: 762320.
4.
Chung HY, Wickel J, Brunkhorst FM, Geis C. Sepsis-associated encephalopathy: from delirium to dementia? J Clin Med 2020; 9: 703.
5.
Dejban P, Nikravangolsefid N, Chamanara M, Dehpour A, Rashidian A. The role of medicinal products in the treatment of inflammatory bowel diseases (IBD) through inhibition of TLR4/NF-kappaB pathway. Phytother Res 2021; 35: 835-845.
6.
Delano MJ, Ward PA. The immune system’s role in sepsis progression, resolution, and long-term outcome. Immunol Rev 2016; 274: 330-353.
7.
Fang, H., Y. Zhang, J. Wang, Li L, An S, Huang Q, Chen Z, Yang H, Wu J, Zeng Z. Remimazolam reduces sepsis-associated acute liver injury by activation of peripheral benzodiazepine receptors and p38 inhibition of macrophages. Int Immunopharmacol 2021; 101 (Pt B): 108331.
8.
Gu M, Mei XL, Zhao YN. Sepsis and cerebral dysfunction: BBB damage, neuroinflammation, oxidative stress, apoptosis and autophagy as key mediators and the potential therapeutic approaches. Neurotox Res 2021; 39: 489-503.
9.
Gül F, Arslantas MK, Cinel I, Kumar A. Changing definitions of sepsis. Turk J Anaesthesiol Reanim 2017; 45: 129-138.
10.
Haileselassie B, Joshi AU, Minhas PS, Mukherjee R, Andreasson KI, Mochly-Rosen D. Mitochondrial dysfunction mediated through dynamin-related protein 1 (Drp1) propagates impairment in blood brain barrier in septic encephalopathy. J Neuroinflammation 2020; 17: 36.
11.
Helbing DL, Bohm L, Witte OW. Sepsis-associated encephalopathy. CMAJ 2018; 190: E1083.
12.
Jia W, Lu R, Martin TA, Jiang WG. The role of claudin-5 in blood-brain barrier (BBB) and brain metastases (review). Mol Med Rep 2014; 9: 779-785.
13.
Jiang S, Wang YQ, Tang Y, Lu X, Guo D. Environmental enrichment protects against sepsis-associated encephalopathy-induced learning and memory deficits by enhancing the synthesis and release of vasopressin in the supraoptic nucleus. J Inflamm Res 2022; 15: 363-379.
14.
Keam SJ. Remimazolam: First approval. Drugs 2020; 80: 625-633.
15.
Kim E, Kim HC, Lee S, Ryu HG, Park YH, Kim JH, Lim YJ, Park HP. Dexmedetomidine confers neuroprotection against transient global cerebral ischemia/reperfusion injury in rats by inhibiting inflammation through inactivation of the TLR-4/NF-kappaB pathway. Neurosci Lett 2017; 649: 20-27.
16.
Li Y, Zhang L, Tang J, Yang X, Huang J, Zhu T, Zhao F, Li S, Li X, Qu Y, Mu D. Role of toll-like receptor 4 in the regulation of the cell death pathway and neuroinflammation. Brain Res Bull 2019; 148: 79-90.
17.
Liao YQ, Min J, Wu ZX, Hu Z. Comparison of the effects of remimazolam and dexmedetomidine on early postoperative cognitive function in elderly patients with gastric cancer. Front Aging Neurosci 2023; 15: 1123089.
18.
Liu X, Lin S, Zhong Y, Shen J, Zhang X, Luo S, Huang L, Zhang L, Zhou S, Tang J. Remimazolam protects against LPS-induced endotoxicity improving survival of endotoxemia mice. Front Pharmacol 2021; 12: 739603.
19.
Pan S, Lv Z, Wang R, Shu H, Yuan S, Yu Y, Shang Y. Sepsis-induced brain dysfunction: Pathogenesis, diagnosis, and treatment. Oxid Med Cell Longev 2022; 2022: 1328729.
20.
Peng X, Luo Z, He S, Zhang L, Li Y. Blood-brain barrier disruption by lipopolysaccharide and sepsis-associated encephalopathy. Front Cell Infect Microbiol 2021; 11: 768108.
21.
Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc 2009; 4: 31-36.
22.
Schuttler J, Eisenried A, Lerch M, Fechner J, Jeleazcov C, Ihmsen H. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: Part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology 2020; 132: 636-651.
23.
Shi M, Chen J, Liu T, Dai W, Zhou Z, Chen L, Xie Y. Protective effects of remimazolam on cerebral ischemia/reperfusion injury in rats by inhibiting of NLRP3 inflammasome-dependent pyroptosis. Drug Des Devel Ther 2022; 16: 413-423.
24.
Silva AYO, Amorim EA, Barbosa-Silva MC, Lima MN, Oliveira HA, Granja MG, Oliveira KS, Fagundes PM, Neris RLS, Campos RMP, Moraes CA, Vallochi AL, Rocco PRM, Bozza FA, Castro-Faria-Neto HC, Maron-Gutierrez T. Mesenchymal stromal cells protect the blood-brain barrier, reduce astrogliosis, and prevent cognitive and behavioral alterations in surviving septic mice. Crit Care Med 2020; 48: e290-e298.
25.
Wesolowski AM, Zaccagnino MP, Malapero RJ, Kaye AD, Urman RD. Remimazolam: Pharmacologic considerations and clinical role in anesthesiology. Pharmacotherapy 2016; 36: 1021-1027.
26.
Yang SF, Zhuang TF, Si YM, Qi K, Zhao J. Coriolus versicolor mushroom polysaccharides exert immunoregulatory effects on mouse B cells via membrane Ig and TLR-4 to activate the MAPK and NF-kappaB signaling pathways. Mol Immunol 2015; 64: 144-151.
27.
Yang Y, Yun D, Dong B, Geng Y, Wan Y. VIP alleviates sepsis-induced cognitive dysfunction as the TLR-4/NF-kappaB signaling pathway is inhibited in the hippocampus of rats. J Mol Histol 2022; 53: 369-377.
28.
Zhao P, Li X, Yang Q, Lu Y, Wang G, Yang H, Dong J, Zhang H. Malvidin alleviates mitochondrial dysfunction and ROS accumulation through activating AMPK-alpha/UCP2 axis, thereby resisting inflammation and apoptosis in SAE mice. Front Pharmacol 2022; 13: 1038802.
29.
Zhu K, Zhu X, Sun S, Yang W, Liu S, Tang Z, Zhang R, Li J, Shen T, Hei M. Inhibition of TLR4 prevents hippocampal hypoxic-ischemic injury by regulating ferroptosis in neonatal rats. Exp Neurol 2021; 345: 113828.
